

## Corporate Medical Policy

### Carotid Intimal-Medial Thickness

**File Name:** carotid\_intimal\_medial\_thickness  
**Origination:** 12/2006  
**Last Review:** 10/2024

#### **Description of Procedure or Service**

---

Ultrasonographic measurement of carotid intimal-medial thickness (CIMT) refers to the use of B-mode ultrasound to determine the thickness of the two innermost layers of the carotid artery wall, the intima and the media. Detection and monitoring of intimal-medial thickening (atherosclerosis) may provide an opportunity to intervene earlier in the atherogenic disease and/or monitor disease progression.

Heart disease is the leading cause of mortality in the United States, accounting for more than half of all deaths. Coronary heart disease (CHD) also known as coronary artery disease, is the most common cause of heart disease. In a 2024 update on heart disease and stroke statistics from the American Heart Association, it was estimated that 720,000 Americans have a new coronary attack (first hospitalization myocardial infarction or CHD death) and 335,000 have a recurrent attack annually.

Established major risk factors for coronary heart disease have been identified by the National Cholesterol Education Program Expert Panel (NCEP). These risk factors include elevated serum levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol and reduced levels of high-density lipoprotein (HDL) cholesterol. Other risk factors include a history of cigarette smoking, hypertension, family history of premature coronary heart disease and age.

The third report of the NCEP Adult Treatment Panel (ATP III) establishes various treatment strategies to modify the risk of coronary heart disease, with emphasis on target goals of LDL-C. Pathology studies have demonstrated that levels of traditional risk factors are associated with the extent and severity of atherosclerosis. The third report of the NCEP recommended use of the Framingham criteria to further stratify those patients with 2 or more risk factors for more intensive lipid management. However, at every level of risk factor exposure, there is substantial variation in the amount of atherosclerosis, presumably related to genetic susceptibility and the influence of other risk factors. There has been interest in identifying a technique that can improve the ability to diagnose those at risk of developing CHD, as well as to measure disease progression, particularly those at intermediate risk.

The carotid arteries can be well visualized by ultrasonography, and ultrasonographic measurement of the carotid intimal-medial thickness (CIMT) and have been investigated as a technique to identify and monitor subclinical atherosclerosis. B-mode ultrasound is most commonly used to measure CIMT. The intimal-medial thickness is measured and averaged over several sites in each carotid artery. Imaging of the far wall of each common carotid artery yields more accurate and reproducible CIMT measurements than imaging of the near wall. Two echogenic lines are produced which represent the lumen-intima interface and the media-adventitia interface. The distance between these two lines constitutes the CIMT.

#### **Regulatory Status**

# Carotid Intimal-Medial Thickness

In 2003, SonoCalc® (SonoSite) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. The FDA determined that this software was substantially equivalent to existing image display products for use in the automatic measurement of the IMT of the carotid artery from images obtained from ultrasound systems. Subsequently, other devices have been approved through the 510(k) process.

***\*\*\*Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

## Policy

---

**Carotid Intimal-Medial Thickness measurement is considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures.**

## Benefits Application

---

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

## When Carotid Intimal-Medial Thickness Measurement is covered

---

Not Applicable

## When Carotid Intimal-Medial Thickness Measurement is not covered

---

Ultrasonographic measurement of carotid artery intimal-medial thickness (CIMT) as a technique of identifying subclinical atherosclerosis is considered investigational for use in the screening, diagnosis, or management of atherosclerotic disease.

## Policy Guidelines

---

The evidence for individuals undergoing cardiac risk assessment who receive ultrasonic measurement of carotid intimal-medial thickness (CIMT), includes large cohort studies, case-control studies, and systematic reviews. Relevant outcomes are test accuracy and morbid events. Some studies correlate increased CIMT with other commonly used markers for risk of coronary heart disease (CHD) and with risk for future cardiovascular events. Lorenz et al (2012) found in their meta-analysis that CIMT was associated with increased CV events, although CIMT progression over time was not associated with increased CV event risk. Peters et al (2012) found that the added predictive value of CIMT was modest, and the ability to reclassify patients into clinically relevant categories was not demonstrated. The results from these reviews and other studies demonstrate the predictive value of CIMT is uncertain, and the predictive ability for any level of population risk cannot be determined with precision. Also, available studies do not define how the use of CIMT in clinical practice improves outcomes. There is no scientific literature that directly tests the hypothesis that measurement of CIMT results in improved patient outcomes and no specific guidance on how measurements of CIMT should be incorporated into risk assessment and risk management. The objective of 1 study, however, was to define "normal" CIMT progression in low to moderate CV risk patients. Study results showed definite patterns related to various factors that could be used as a tool to earlier identify patients at increased CV

# Carotid Intimal-Medial Thickness

risk, but patient outcomes were not assessed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The U.S. Preventive Services Task Force (USPSTF, 2009) stated that there was insufficient evidence to recommend the use of carotid intima-medial thickness to screen asymptomatic individuals with no history of CHD to prevent CHD events. In 2018, the USPSTF published a statement on using nontraditional risk factors to assess the risk of CVD; CIMT was not recommended. In 2018, the USPSTF published a recommendation statement on using nontraditional risk factors to assess the risk of CVD; CIMT was not mentioned in this recommendation.

The 2013 guidelines on the assessment of cardiovascular risk from the American College of Cardiology and the American Heart Association (ACC/AHA) did not recommend CIMT for routine risk assessment of a first atherosclerotic cardiovascular disease event (ACC/AHA Class III: no benefit, LOE: B). This differs from the previous 2010 version of the ACC/AHA guidelines for assessment of cardiovascular risk, which indicated CIMT might be reasonable for assessing cardiovascular risk in intermediate risk asymptomatic adults.

## Billing/Coding/Physician Documentation Information

---

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at [www.bcbsnc.com](http://www.bcbsnc.com). They are listed in the Category Search on the Medical Policy search page.

*Applicable codes: 93895, 93998*

*CPT 93880 describes bilateral duplex scan of extracranial arteries. Because of the detailed measurement involved in calculating carotid intimal-medial thickness, providers may elect to submit these claims with a --22 modifier (unusual procedural service). In addition, linking the CPT code to the ICD-10 code Z13.6 (Encounter for screening for cardiovascular disorders) may help identify claims.*

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

## Scientific Background and Reference Sources

---

Simons PC, Algra A, Bots ML, Grobbee DE, van der Graaf Y. (August 1999). Common Carotid Intima-Media Thickness and Arterial Stiffness: Indicators of Cardiovascular Risk in High-Risk Patient The SMART Study (Second Manifestations of ARterial disease). *Circulation*. 1999;100:951-957

O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. (January 1999). Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults. *New England Journal of Medicine*. 1999;340(1):14-22

Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JC. (June 2002). Carotid intima-media thickness at different sites: relation to incident myocardial infarction. *European Heart Journal*, 2002; 23(12):934-940

U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute. Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult

## Carotid Intimal-Medial Thickness

Treatment Panel III). Final Report. NIH Publication No. 02-5215. September 2002. Retrieved November 7, 2006 from <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf>

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 8/17/05

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 6/11/09

National Institutes of Health (NIH). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 02-5215. September 2002. Retrieved on September 9, 2010 from <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf>

U.S. Preventative Services Task Force. Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment Recommendation Statement. October 2009. Retrieved on September 9, 2010 from <http://www.uspreventiveservicestaskforce.org/uspstf09/riskcoronaryhd/coronaryhdrs.htm>

Helfand M, Buckley D, Fleming C, et al. Screening for Intermediate Risk Factors for Coronary Heart Disease. U.S. Preventive Services Task Force Evidence Syntheses. Agency for Healthcare Research and Quality (US); 2009. Report No.: 10-05141-EF-1. Retrieved on September 9, 2010 from <http://www.ncbi.nlm.nih.gov/pubmed/20722172>.

Lloyd-Jones D, Adams RJ, Brown TM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2010 Update. A Report From the American Heart Association. *Circulation*. 2009 Dec 17. Retrieved on September 9, 2010 from <http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192667v1>

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 7/8/10

Specialty Matched Consultant Advisory Panel review 10/2010

National Institutes of Health (NIH). Using Differences in Peripheral Blood Leukocyte Gene Expression to Determine Cardiovascular Disease Risk. Clinical Trial #NCT00613158

National Institutes of Health (NIH). Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases. (PRIMARIA). Clinical Trial #NCT00734123

National Institutes of Health (NIH). Intima-Medial Thickness Guidance of Primary Prevention in Relatives of Patients With Early onset Atherosclerosis (IMPRESS). Clinical Trial #NCT01330602

Greenland P, Alpert JS, Beller GA et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; 56(25):e50-103. Retrieved on August 15, 2011 from <http://www.asnc.org/imageuploads/CV%20Risk.pdf>

BCBSA Medical Policy Reference Manual [Electronic Version]. 02.02.16, 7/14/11

Specialty Matched Consultant Advisory Panel review 10/2011

BCBSA Medical Policy Reference Manual [Electronic Version]. 02.02.16, 7/12/12

Specialty Matched Consultant Advisory Panel review 10/2012

## Carotid Intimal-Medial Thickness

Lorenz MW, Schaefer C, Steinmetz H et al. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). *Eur Heart J* 2010; 31(16):2041-8.

Den Ruijter HM, Peters SA, Anderson TJ et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. *JAMA* 2012; 308(8):796-803.

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 7/11/13

Specialty Matched Consultant Advisory Panel review 10/2013

Medical Director review 10/2013

Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Jun 24 2014; 129(25 Suppl 2): S49-73. PMID 24222018

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 7/10/14

Specialty Matched Consultant Advisory Panel review 11/2014

Medical Director review 11/2014

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 7/9/15

Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *Lancet*. Jun 2 2012;379(9831):2053-2062. PMID 22541275

Medical Director review 7/2015

Specialty Matched Consultant Advisory Panel review 10/2015

Medical Director review 10/2015

Specialty Matched Consultant Advisory Panel review 10/2016

Medical Director review 10/2016

Specialty Matched Consultant Advisory Panel review 10/2017

Medical Director review 10/2017

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 5/2018

Medical Director review 5/2018

Specialty Matched Consultant Advisory Panel review 10/2018

Medical Director review 10/2018

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 6/2019

Specialty Matched Consultant Advisory Panel review 10/2019

# Carotid Intimal-Medial Thickness

Medical Director review 10/2019

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 6/2020

Specialty Matched Consultant Advisory Panel review 10/2020

Medical Director review 10/2020

BCBSA Medical Policy Reference Manual [Electronic Version]. 2.02.16, 6/2021

Specialty Matched Consultant Advisory Panel review 10/2021

Medical Director review 10/2021

Specialty Matched Consultant Advisory Panel review 10/2022

Medical Director review 10/2022

Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*. Feb 21 2023; 147(8): e93-e621. PMID 36695182

Pasternak RC. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. *Cardiol Clin*. Aug 2003; 21(3): 393-8. PMID 14621453

Curry SJ, Krist AH, Owens DK, et al. Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. *JAMA*. Jul 17 2018; 320(3): 272-280. PMID 29998297

Specialty Matched Consultant Advisory Panel review 10/2023

Medical Director review 10/2023

Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. *Circulation*. Feb 20 2024; 149(8): e347-e913. PMID 38264914

Calonge N, Petitti DB, DeWitt TG, et al. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. Oct 06 2009; 151(7): 474-82. PMID 19805770

Specialty Matched Consultant Advisory Panel review 10/2024

Medical Director review 10/2024

## Policy Implementation/Update Information

---

12/11/06 New Policy issued. Ultrasonographic measurement of carotid artery intima-media thickness (IMT) is considered investigational as a technique of identifying and monitoring subclinical atherosclerosis. (adn)

# Carotid Intimal-Medial Thickness

11/19/07 Specialty Matched Consultant Advisory Panel review meeting 10/29/07. Policy accepted as written. (adn)

## **Policy renamed: Carotid Intimal-Medial Thickness Study**

7/20/09 Policy name changed from Common Carotid Intima-Media Thickness Study to Carotid Intimal-Medial Thickness Study. Description section revised. Policy statement revised to read: "BCBSNC does not provide coverage for carotid intimal-medial thickness studies. It is considered investigational." Statement in the When Not Covered section was revised to read: "Ultrasonographic measurement of carotid artery intimal-medial thickness (IMT) as a technique of identifying subclinical atherosclerosis is considered investigational for use in the screening, diagnosis, or management of atherosclerotic disease." Coding information added to the Billing/Coding section. (adn)

12/7/09 Specialty Matched Consultant Advisory Panel review meeting 10/30/09. No change to policy statement.(adn)

6/22/10 Policy Number(s) removed (amw)

11/23/10 Specialty Matched Consultant Advisory Panel review 10/2010. Policy Guidelines updated. References updated.(mco)

8/30/11 References updated. Policy Guidelines updated. No changes to Policy Statements. (mco)

11/8/11 Specialty Matched Consultant Advisory Panel review 10/2011. No changes to Policy Statements.(mco)

9/4/12 References updated. No changes to Policy Statements. (mco)

10/30/12 Specialty Matched Consultant Advisory Panel review 10/2012. Description section updated. Policy Guidelines updated. (mco)

8/27/13 References updated. No changes to Policy Statements. (mco)

11/12/13 Specialty Matched Consultant Advisory Panel review 10/2013. Medical Director review 10/2013. Removed the word "Study" from the policy title. Policy Statement revised to state: "Carotid Intimal-Medial Thickness measurement is considered investigational for all applications. BCBSNC does not provide coverage for investigational services or procedures." Policy intent is unchanged. (mco)

8/26/14 References updated. Policy Guidelines updated. No changes to Policy Statement. (mco)

12/30/14 References updated. Specialty Matched Consultant Advisory Panel review 11/2014. Medical Director review 11/2014. Added CPT code 93895 to Billing/Coding section effective 1/1/15. No changes to Policy statement. (td)

10/1/15 Policy Description updated. Policy Guidelines updated. References updated. Policy intent remains unchanged. Medical Director review 7/2015. (td)

1/26/16 Specialty Matched Consultant Advisory Panel review 10/29/2015. Medical Director review 10/2015. (td)

## Carotid Intimal-Medial Thickness

- 11/22/16 Specialty Matched Consultant Advisory Panel review 10/2016. Medical Director review 10/2016. (jd)
- 11/10/17 Minor revisions to Description section and Policy Guidelines. Specialty Matched Consultant Advisory Panel review 10/2017. Medical Director review 10/2017. (jd)
- 6/8/18 Policy guidelines and references updated. Medical Director review 5/2018. (jd)
- 11/9/18 Minor update to the Billing/Coding section. Specialty Matched Consultant Advisory Panel review 10/2018. Medical Director review 10/2018. (jd)
- 10/29/19 References updated. Specialty Matched Consultant Advisory Panel review 10/2019. Medical Director review 10/2019. (jd)
- 11/10/20 References updated. Specialty Matched Consultant Advisory Panel review 10/2020. Medical Director review 10/2020. (jd)
- 11/2/21 Description section, policy guidelines, and references updated. Specialty Matched Consultant Advisory Panel review 10/2021. Medical Director review 10/2021. (jd)
- 11/1/22 Minor edits to Description section for clarity, References updated. No change to policy statement. Specialty Matched Consultant Advisory Panel review 10/2022. Medical Director review 10/2022. (tm)
- 11/7/23 Description section, Policy Guidelines, and References updated. Specialty Matched Consultant Advisory Panel review 10/2023. Medical Director review 10/2023. (tm)
- 11/13/24 Description and References updated. Specialty Matched Consultant Advisory Panel review 10/2024. Medical Director review 10/2024. (tm)

---

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.